Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$4.05 -0.7%	$5.49	$2.90 ▼ $11.16	$330.92M	0.47	3.37 million shs	3.01 million shs
ARWR Arrowhead Pharmaceuticals	$14.71 -12.2%	$16.34	$9.57 ▼ $29.86	$2.31B	0.93	1.60 million shs	6.75 million shs
BHC Bausch Health Cos	$6.34 +0.4%	$5.60	$3.96 ▼ $9.85	$2.34B	0.41	2.52 million shs	1.01 million shs
NAMS NewAmsterdam Pharma	$22.56 +1.6%	$19.35	$14.06 ▼ $27.29	$2.49B	-0.03	744,478 shs	881,104 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-0.74%	-4.93%	-42.54%	-16.49%	-35.51%
ARWR Arrowhead Pharmaceuticals	-12.23%	-20.96%	-3.98%	+19.01%	-48.02%
BHC Bausch Health Cos	+0.41%	+0.02%	+2.69%	+21.96%	-16.63%
NAMS NewAmsterdam Pharma	+1.62%	+1.76%	+25.61%	+34.37%	+19.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.0091 of 5 stars	3.4	1.0	0.0	2.3	1.7	0.6
ARWR Arrowhead Pharmaceuticals	3.8988 of 5 stars	3.4	2.0	3.4	3.9	1.7	0.0
BHC Bausch Health Cos	3.4891 of 5 stars	1.9	4.0	4.0	0.6	3.3	0.6
NAMS NewAmsterdam Pharma	3.6021 of 5 stars	4.4	2.0	0.0	1.9	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.75	Moderate Buy	$18.20	349.38% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	197.17% Upside
BHC Bausch Health Cos	1.83	Reduce	$7.30	15.21% Upside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.30	83.07% Upside

Current Analyst Ratings Breakdown

Latest ALT, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,424.78	N/A	N/A	$1.74 per share	2.33
ARWR Arrowhead Pharmaceuticals	$3.55M	572.24	N/A	N/A	$1.54 per share	9.55
BHC Bausch Health Cos	$9.63B	0.24	$7.73 per share	0.82	($0.89) per share	-7.12
NAMS NewAmsterdam Pharma	$45.56M	55.59	N/A	N/A	$8.20 per share	2.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	19.71	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.36	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)

Latest ALT, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALT Altimmune	-$0.3006	N/A	N/A	N/A	$0.00 million	N/A
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	N/A	N/A	N/A	$1.44 million	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.12%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.09 million	340.04 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable

ALT, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

1 hour ago | globenewswire.com

Atle Fund Management AB Cuts Stock Holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

July 19 at 9:12 AM | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Sold by Jennison Associates LLC

July 19 at 7:30 AM | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns Neutral Rating from Analysts at The Goldman Sachs Group

July 19 at 2:01 AM | americanbankingnews.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells $1,019,879.36 in Stock

July 18, 2025 | marketbeat.com

Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 51,043 Shares of Stock

July 18, 2025 | marketbeat.com

Douglas F. Kling Sells 47,569 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

July 18, 2025 | insidertrades.com

Goldman Sachs Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Neutral Recommendation

July 17, 2025 | msn.com

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs Group

July 17, 2025 | marketbeat.com

Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS)

July 16, 2025 | msn.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Buy" from Analysts

July 14, 2025 | americanbankingnews.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Buy" from Analysts

July 14, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 5.7% - Still a Buy?

July 9, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street Zen

July 5, 2025 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

June 27, 2025 | insidertrades.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

June 26, 2025 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 2,520 Shares

June 26, 2025 | marketbeat.com

First Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq

June 24, 2025 | nasdaq.com

NewAmsterdam Pharma Company N.V. (NAMS) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

James N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 19, 2025 | insidertrades.com

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug

June 18, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Do They Know Something? Insiders & Congress Buy UnitedHealth
By Brian O'Connell | July 9, 2025
View Do They Know Something? Insiders & Congress Buy UnitedHealth
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
By Leo Miller | July 17, 2025
View Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals

ALT, NAMS, BHC, and ARWR Company Descriptions

Altimmune NASDAQ:ALT

$4.05 -0.03 (-0.74%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$4.09 +0.04 (+0.99%)

As of 08:15 AM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$14.71 -2.05 (-12.23%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$14.80 +0.09 (+0.65%)

As of 08:10 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.34 +0.03 (+0.41%)

Closing price 07/21/2025 03:58 PM Eastern

Extended Trading

$6.35 +0.01 (+0.16%)

As of 04:00 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$22.56 +0.36 (+1.62%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$22.59 +0.03 (+0.13%)

As of 08:15 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time